Mark Frohlich Email

CEO . Indapta Therapeutics

Seattle & Houston,

Location

Current Roles

Employees:
29
Revenue:
$5.4M
About
Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.
Indapta Therapeutics Address

Seattle & Houston, null
United States
Indapta Therapeutics Email